Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection

[1] Liu W(2014)Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo Mol Med Rep 10 1921-6

[2] Xu J(2015)Updated UK Recommendations for HER2 assessment in breast cancer J Clin Pathol 68 93-9

[3] Liu Y(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 236-44

[4] Yu X(2010)Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 377-84

[5] Tang X(2012)Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 633-40

[6] Wang Z(2014)HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Mod Pathol 27 4-18

[7] Rakha EA(2000)Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization Mod Pathol 13 37-45

[8] Pinder SE(2006)HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial J Clin Oncol 24 3032-8

[9] Bartlett JM(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18-43

[10] Ibrahim M(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 3997-4013

[1] Liu W(2014)Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo Mol Med Rep 10 1921-6

[2] Xu J(2015)Updated UK Recommendations for HER2 assessment in breast cancer J Clin Pathol 68 93-9

[3] Liu Y(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 236-44

[4] Yu X(2010)Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 377-84

[5] Tang X(2012)Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 633-40

[6] Wang Z(2014)HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Mod Pathol 27 4-18

[7] Rakha EA(2000)Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization Mod Pathol 13 37-45

[8] Pinder SE(2006)HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial J Clin Oncol 24 3032-8

[9] Bartlett JM(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18-43

[10] Ibrahim M(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 3997-4013